Literature DB >> 24935383

An epigenetic mechanism underlying doxorubicin induced EMT in the human BGC-823 gastric cancer cell.

Rong-Fei Han1, Xiang Ji, Xing-Gao Dong, Rui-Jing Xiao, Yan-Ping Liu, Jie Xiong, Qiu-Ping Zhang.   

Abstract

The epithelial to mesenchymal transition (EMT) is a key step during embryonic morphogenesis and plays an important role in drug resistance and metastasis in diverse solid tumors. We previously reported that 48 h treatment of anti-cancer drug doxorubicin could induce EMT in human gastric cancer BGC-823 cells. However, the long term effects of this transient drug treatment were unknown. In this study we found that after 48 h treatment with 0.1 μg/ml doxorubicin, most cells died during next week, while a minor population of cells survived and formed colonies. We propagated the surviving cells in drug free medium and found that these long term cultured drug survival cells (abbreviated as ltDSCs) retained a mesenchymal-like cell morphology, and expressed high levels of EMT-related molecules such as vimentin, twist and β-catenin. The expression of chromatin reprogramming factors, Oct4 and c-myc, were also higher in ltDSCs than parental cells. We further demonstrated that the protein level of p300 was upregulated in ltDSCs, and inhibition of p300 by siRNA suppressed the expression of vimentin. Moreover, the ltDSCs had higher colony forming ability and were more drug resistant when compared to parental cells. Our results suggested that an epigenetic mechanism is involved in the EMT of ltDSCs.

Entities:  

Mesh:

Substances:

Year:  2014        PMID: 24935383     DOI: 10.7314/apjcp.2014.15.10.4271

Source DB:  PubMed          Journal:  Asian Pac J Cancer Prev        ISSN: 1513-7368


  8 in total

1.  CNTN-1 Upregulation Induced by Low-Dose Cisplatin Promotes Malignant Progression of Lung Adenocarcinoma Cells via Activation of Epithelial-Mesenchymal Transition.

Authors:  Ruijie Zhang; Shengjin Li; Jian Lan; Changyi Li; Xianzhi Du; Weijie Dong; Qian Yu; Daoxin Wang
Journal:  Front Genet       Date:  2022-05-27       Impact factor: 4.772

Review 2.  Epithelial-mesenchymal transition in gastric cancer.

Authors:  Lei Huang; Ruo-Lin Wu; A-Man Xu
Journal:  Am J Transl Res       Date:  2015-11-15       Impact factor: 4.060

3.  Notch signaling is important for epithelial-mesenchymal transition induced by low concentrations of doxorubicin in osteosarcoma cell lines.

Authors:  Jian Yang; Weichun Guo; Lu Wang; Ling Yu; Hongjun Mei; Shuo Fang; Anyuan Chen; Yang Liu; Kezhou Xia; Gaiwei Liu
Journal:  Oncol Lett       Date:  2017-02-09       Impact factor: 2.967

4.  TGF-β-Induced TMEPAI Promotes Epithelial-Mesenchymal Transition in Doxorubicin-Treated Triple-Negative Breast Cancer Cells via SMAD3 and PI3K/AKT Pathway Alteration.

Authors:  Bantari W K Wardhani; Melva Louisa; Yukihide Watanabe; Rianto Setiabudy; Mitsuyasu Kato
Journal:  Breast Cancer (Dove Med Press)       Date:  2021-09-21

5.  Blocking epithelial-to-mesenchymal transition in glioblastoma with a sextet of repurposed drugs: the EIS regimen.

Authors:  Richard E Kast; Nicolas Skuli; Georg Karpel-Massler; Guido Frosina; Timothy Ryken; Marc-Eric Halatsch
Journal:  Oncotarget       Date:  2017-06-01

6.  Tamoxifen reverses epithelial-mesenchymal transition by demethylating miR-200c in triple-negative breast cancer cells.

Authors:  Qian Wang; Yu Cheng; Yan Wang; Yibo Fan; Ce Li; Ye Zhang; Yiding Wang; Qian Dong; Yanju Ma; Yue-E Teng; Xiujuan Qu; Yunpeng Liu
Journal:  BMC Cancer       Date:  2017-07-19       Impact factor: 4.430

7.  DUSP4 promotes doxorubicin resistance in gastric cancer through epithelial-mesenchymal transition.

Authors:  Xing Kang; Minhuan Li; Hao Zhu; Xiaofeng Lu; Ji Miao; Shangce Du; Xuefeng Xia; Wenxian Guan
Journal:  Oncotarget       Date:  2017-10-04

8.  Ubenimex induces autophagy inhibition and EMT suppression to overcome cisplatin resistance in GC cells by perturbing the CD13/EMP3/PI3K/AKT/NF-κB axis.

Authors:  Qie Guo; Fan-Jing Jing; Wen Xu; Xiao Li; Xin Li; Jia-Lin Sun; Xiao-Min Xing; Chang-Kai Zhou; Fan-Bo Jing
Journal:  Aging (Albany NY)       Date:  2019-12-31       Impact factor: 5.682

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.